Effect of G(-174)C polymorphism in interleukin-6 gene on cardiovascular disease in type 2 diabetes patients

Buraczyńska, Monika; Żukowski, Paweł; Drop, Bartłomiej; Baranowicz-Gąszczyk, Iwona; Książek, Andrzej

doi:10.1016/j.cyto.2015.12.004

Cited by 20 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An association between Helicobacter pylori infection and decreased high-density lipoprotein (HDL) levels could be transmitted through its genotype of the IL-6 gene [14]. In patients with type 2 diabetes, rs1800795 SNP of the IL-6 gene is significantly related to increased risk of cardiovascular disease [15]. In addition, rs1800795 SNP of the IL-6 gene is related with autoimmune diseases such as systemic lupus erythematosus [16], systemic sclerosis [17], and autoimmune thyroid disease [18].…”

Section: Introductionmentioning

confidence: 99%

Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis

2016

View full text Add to dashboard Cite

BackgroundIschemic stroke and myocardial infarction are fatal diseases and are among the top 10 causes of death in Korea, including arterial thromboembolic events. Many previous studies have described the function of interleukin-6 (IL-6) in arterial thromboembolic events and the association between promoter single-nucleotide polymorphism (SNP) (rs1800795; −174, G/C) of the IL-6 gene. However, these results were controversial. Therefore, we performed a meta-analysis to more precisely assess the association between the SNP of the IL-6 gene and susceptibility to arterial thromboembolic events.Material/MethodsWe used PubMed, Embase, Google Scholar, and Korean Studies Information Service System (KISS) electronic databases. Comprehensive Meta-analysis software (Corporation, NJ) was used to evaluate the relationship between rs1800795 SNP of IL-6 gene and risk of arterial thromboembolic events. Odds ratio (OR), 95% confidence interval (CI), and P value were also calculated. The 13 eligible studies were analyzed in the meta-analysis.ResultsThe present meta-analysis found that rs1800795 SNP of IL-6 gene is not significantly associated with susceptibility to arterial thromboembolic events (C allele vs. G allele, OR=1.04, 95% CI=0.91–1.19, P=0.619; CC vs. CG+GG, OR=1.09, 95% CI=0.91–1.31, P=0.364; CC+CG vs. GG, OR=0.97, 95% CI=0.78–1.21, P=0.763, respectively), and the SNP of IL-6 gene also did not show any significant association with ischemic stroke or myocardial infarction (P>0.05 in each model).ConclusionsWe found that rs1800795 SNP of IL-6 gene was not related to arterial thromboembolic events. However, further study will be needed to confirm these results.

show abstract

Section: Introductionmentioning

confidence: 99%

Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis

2016

View full text Add to dashboard Cite

show abstract

“…The mechanisms might include severe coronary endothelial dysfunction because of increased oxidative stress caused by high glucose, [18,33] increased platelet adhesion that promotes venous thrombosis, [19,34] and enhanced inflammatory responses, which cause the progression of atherosclerosis or vascular injury. [20,35,36] Furthermore, poor glycemic control may lead to an increased conformation of advanced glycation end products, which may cause severe vascular damage. [18] Therefore, HbA1c, which reflects metabolic control and embedded ongoing vascular injury or atherosclerosis, may be considered a reliable indicator of adverse outcomes in nondiabetic populations after AMI.…”

Section: Discussionmentioning

confidence: 99%

Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients

Chen¹,

Yen

Lin³

et al. 2017

Medicine

View full text Add to dashboard Cite

The effect of glycemic control on the prognosis of nondiabetic patients after acute myocardial infarction (AMI) remains uncertain. We investigated whether glycated hemoglobin (HbA1c) is associated with adverse outcomes after AMI in nondiabetic patients. In this observational study, we enrolled nondiabetic patients with AMI in the emergency department of 2 medical centers from January 2011 to September 2014. All patients received primary percutaneous coronary intervention and were divided into 4 groups according to the interquartile range of average HbA1c level (Group I, ≤5.6%; Group II, 5.6%–5.8%; Group III, 5.8%–6.0%; and Group IV, >6.0%). Multivariate logistic analysis was performed to estimate the correlation of HbA1c with major adverse cardiac events (MACEs) after AMI. In total, 267 eligible patients were enrolled; 48 patients (18%) developed MACEs within a median follow-up of 178 days. Univariate analysis showed HbA1c > 6.0%, with a higher risk of MACEs in Group IV than in Group I (odds ratio [OR]: 2.733; 95% confidence interval [CI]: 1.123–6.651 vs OR: 1.511; 95% CI: 0.595–3.835). Multivariate analysis revealed an approximately 3.8 times higher risk of MACEs in Group IV than in Group I (OR: 3.769; 95% CI: 1.30–10.86). The HbA1 level is a significant predictor of MACEs after AMI in nondiabetic patients.

show abstract

“…It is reported that the gene polymorphisms of inflammatory cytokine could affect cytokine mRNA transcription and thus change the serum levels of inflammatory cytokine (Larcombe et al, 2005). In the recent studies, emphasis often be focused on investigating the role of IL-6 polymorphisms to several kinds of diseases, such as chronic obstructive pulmonary disease, cardiovascular disease, HBV-related liver disease, or osteoporosis (Chang et al, 2015;Xie et al, 2015;Buraczynska et al, 2016). In our study, we carried out a study to investigate the role of IL-6 polymorphisms in the risk of CAD, and we revealed that the IL-6 -174G/C genomic polymorphism was correlated with an elevated risk to CAD in multiple genetic models.…”

Section: Discussionmentioning

confidence: 99%

“…The IL-6 gene, located at chromosome 7p21-24, is composed of 4 introns and 5 exons. Since single nucleotide polymorphisms of IL-6 gene promoter may affect the expression and secretion of IL-6, and subsequently the altered circulating levels might result in relevant biological responses, and the IL-6 polymorphism has been regarded as a crucial modulator in pathogenesis of various diseases, including Alzheimer's disease, type 2 diabetes, celiac disease, chronic obstructive pulmonary disease and osteoarthritis (de Albuquerque Maranhão et al, 2015;Fernandes et al, 2015;Xie et al, 2015;Buraczynska et al, 2016;Ramos Dos Santos et al, 2016). Although several studies have shown that IL-6 polymorphisms could be also involved in the development of CAD, the conclusions were not consistent Liu et al, 2015;Wang et al, 2015;Yang et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Interleukin-6 (IL-6) -174G/C genomic polymorphism contribution to the risk of coronary artery disease in a Chinese population

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT.To investigate the role of IL-6 polymorphism (-174G/C and -572C/G) in the development of coronary artery disease (CAD), CAD patients (224) and control subjects (260) were recruited between January 2012 and December 2014. Genotyping at IL-6 -174G/C and -572C/G was conducted via polymerase chain reaction coupled to restriction fragment length polymorphism. Results indicated that several disease risk factors were significantly higher in CAD patients as compared to the control subjects. These factors include hypertension (χ 2 = 20.03, P < 0.001), diabetes mellitus (χ 2 = 33.53, P < 0.001), tobacco smoking (χ 2 = 28.17, P < 0.001), body mass indexes (t = 11.39, P < 0.001), total cholesterol (t = 8.25, P < 0.001), low-density lipoprotein cholesterol (t = 7.24, P < 0.001), high-density lipoprotein cholesterol (t = 3.52, P < 0.001), and triglyceride (t = 6.09, P < 0.001). By unconditional logistic regression analysis, we observed that the CC genotype at IL-6 -174G/C was had a 2.32 (95%CI = 1.33-4.06) fold risk of developing CAD compared to the GG genotype. Moreover, IL-6 -174G/C polymorphism was positively associated with the risk of developing CAD in both dominant (OR = 1.63, 95%CI = 1.12-2.38; P = 0.01) and recessive models (OR = 2.18, 95%CI = 1.26-3.77; P = 0.001). However, no statistically significant association was observed between IL-6 -572C/G polymorphism and risk of CAD. In conclusion, IL-6 -174G/C polymorphisms are associated with the pathogenesis of CAD.

show abstract

Effect of G(-174)C polymorphism in interleukin-6 gene on cardiovascular disease in type 2 diabetes patients

Cited by 20 publications

References 36 publications

Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis

Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis

Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients

Interleukin-6 (IL-6) -174G/C genomic polymorphism contribution to the risk of coronary artery disease in a Chinese population

Contact Info

Product

Resources

About